TY  - JOUR
AU  - Zhang, B.
AU  - Yu, W.
AU  - Zhao, Q.T.
AU  - Buca, D.
AU  - Holländer, B.
AU  - Hartmann, J.M.
AU  - Zhang, M.
AU  - Wang, X.
AU  - Mantl, S.
TI  - Improved NiSi0.8Ge0.2/Si0.8Ge0.2 Contacs by C+ Pre-Implantation
JO  - Electrochemical and solid-state letters
VL  - 14
SN  - 1099-0062
CY  - Pennington, NJ
PB  - Soc.
M1  - PreJuSER-15880
SP  - H261-H263
PY  - 2011
N1  - This work was supported by the German Federal Ministry of Education and Research via the MEDEA+ project DECI-SIF(2T104). Additional funding was received by the Nanosil network from the European Community (FP7 grant No. 216171). B. Zhang thanks the National Natural Science Foundation of China under Grant No. 61006088 and, together with W. Yu to the China Scholarship Council for the financial support.
AB  - This open-label extension evaluated the long-term efficacy and tolerability of rufinamide in patients with Lennox-Gastaut syndrome (LGS) who had previously completed a 12-week double-blind study.In total, 124 patients (aged 4-37 years), receiving 1-3 concomitant antiepileptic drugs, were treated with rufinamide approximately 25-60 mg/kg/day. Efficacy was assessed by seizure frequency; tolerability by adverse events (AEs) and laboratory tests.Overall, patients were treated with rufinamide for a median (range) of 432 (10-1149) days. Reductions in seizure frequency were observed throughout the study; during the last 12 months of treatment, 41.0% and 47.9% of patients had > or = 50% reduction in total and tonic-atonic seizure frequency, respectively. The most common AEs were vomiting (30.6%) and pyrexia (25.8%).In this open-label extension, rufinamide appeared to be an effective long-term adjunctive therapy for the treatment of LGS-associated seizures in children and young adults.
KW  - J (WoSType)
LB  - PUB:(DE-HGF)16
UR  - <Go to ISI:>//WOS:000290276400011
DO  - DOI:10.1149/1.3578387
UR  - https://juser.fz-juelich.de/record/15880
ER  -